Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
- 29 July 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 108 (4), 420-425
- https://doi.org/10.1161/01.cir.0000080884.27358.49
Abstract
Background— The clustering of impaired glucose metabolism, elevated triglycerides, low HDL cholesterol, and abdominal obesity is known as the metabolic syndrome. Individuals with this syndrome suffer an excess of cardiovascular disease (CVD) for reasons that are unclear. Methods and Results— We randomly sampled 1276 adults of South Asian, Chinese, European, and Native Indian ancestry from 4 communities in Canada. Participants provided fasting blood samples for glucose, lipids, and fibrinolytic measurements; had an oral glucose tolerance test; and underwent a B-mode carotid ultrasound examination. CVD was determined by history and ECG. The prevalence of the metabolic syndrome was 25.8% (95% CI, 23.5 to 28.2) and varied substantially by ethnic group: 41.6% among Native Indians, 25.9% among South Asians, and 22.0% among Europeans, compared with 11.0% among the Chinese (overall, P =0.0001). People with the metabolic syndrome had more atherosclerosis (maximum intimal medial thickness, 0.78±0.18 versus 0.74±0.18 mm; P =0.0005), CVD (17.2% versus 7.0%; P =0.0001), and elevated plasminogen activator inhibitor-1 (24.2 versus 14.6 U/mL; P =0.001) compared with levels among people without the metabolic syndrome. For the same amount of atherosclerosis, people with the metabolic syndrome had a greater prevalence of CVD, even among nondiabetic individuals. This difference in CVD prevalence among the groups was attenuated after adjustment for plasminogen activator inhibitor-1 levels, suggesting that fibrinolytic dysfunction mediates the increased risk of CVD in individuals with the metabolic syndrome. Conclusion— CVD among people with the metabolic syndrome is explained by their excess of atherosclerosis and impaired fibrinolysis. Interventions to prevent atherosclerosis progression and improve fibrinolytic function require evaluation in this high-risk group.Keywords
This publication has 26 references indexed in Scilit:
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002
- Plasminogen-Activator Inhibitor Type 1 and Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina PectorisNew England Journal of Medicine, 1995
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosisDiabetologia, 1991
- Determination of plasminogen activator inhibitor in plasma using t-pa and a chromogenic single-point poly-D-lysine stimulated assayThrombosis Research, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.BMJ, 1984